Esraa A. Ahmed

648 total citations · 1 hit paper
23 papers, 470 citations indexed

About

Esraa A. Ahmed is a scholar working on Pharmacology, Epidemiology and Complementary and alternative medicine. According to data from OpenAlex, Esraa A. Ahmed has authored 23 papers receiving a total of 470 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pharmacology, 5 papers in Epidemiology and 5 papers in Complementary and alternative medicine. Recurrent topics in Esraa A. Ahmed's work include Liver Disease Diagnosis and Treatment (4 papers), Drug-Induced Hepatotoxicity and Protection (4 papers) and Chemotherapy-induced organ toxicity mitigation (3 papers). Esraa A. Ahmed is often cited by papers focused on Liver Disease Diagnosis and Treatment (4 papers), Drug-Induced Hepatotoxicity and Protection (4 papers) and Chemotherapy-induced organ toxicity mitigation (3 papers). Esraa A. Ahmed collaborates with scholars based in Egypt, Saudi Arabia and United States. Esraa A. Ahmed's co-authors include ‏Helal F. Hetta, Noura H. Abd Ellah, Basem Battah, Stefania Zanetti, Alhanouf I. Al-Harbi, Matthew Gavino Donadu, Yasmin N. Ramadan, Rasha B. Abd-ellatief, Mohamed A. El‐Mokhtar and Azza Elkady and has published in prestigious journals such as Scientific Reports, International Journal of Nanomedicine and Phytotherapy Research.

In The Last Decade

Esraa A. Ahmed

21 papers receiving 462 citations

Hit Papers

Nanotechnology as a Promising Approach to Combat Multidru... 2023 2026 2024 2025 2023 50 100 150

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Esraa A. Ahmed Egypt 9 156 104 77 73 37 23 470
Saumya Ray Chaudhuri India 10 95 0.6× 214 2.1× 93 1.2× 57 0.8× 27 0.7× 12 550
H. Rajeshwari India 8 196 1.3× 68 0.7× 39 0.5× 135 1.8× 45 1.2× 13 557
Shumaila Mumtaz Pakistan 13 137 0.9× 80 0.8× 26 0.3× 54 0.7× 45 1.2× 26 486
Turki Al Hagbani Saudi Arabia 14 107 0.7× 123 1.2× 56 0.7× 83 1.1× 22 0.6× 37 530
Fahad A. Almughem Saudi Arabia 14 58 0.4× 203 2.0× 41 0.5× 72 1.0× 33 0.9× 30 570
Khalid Al‐Batayneh Jordan 12 243 1.6× 141 1.4× 27 0.4× 93 1.3× 71 1.9× 34 583
Banu Mansuroğlu Türkiye 13 88 0.6× 190 1.8× 65 0.8× 96 1.3× 34 0.9× 37 652
Maha Alharbi Saudi Arabia 10 68 0.4× 84 0.8× 45 0.6× 36 0.5× 20 0.5× 20 363
Topu Raihan Bangladesh 12 132 0.8× 155 1.5× 26 0.3× 156 2.1× 46 1.2× 23 562
Foziyah Zakir India 14 65 0.4× 131 1.3× 58 0.8× 42 0.6× 45 1.2× 28 704

Countries citing papers authored by Esraa A. Ahmed

Since Specialization
Citations

This map shows the geographic impact of Esraa A. Ahmed's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Esraa A. Ahmed with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Esraa A. Ahmed more than expected).

Fields of papers citing papers by Esraa A. Ahmed

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Esraa A. Ahmed. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Esraa A. Ahmed. The network helps show where Esraa A. Ahmed may publish in the future.

Co-authorship network of co-authors of Esraa A. Ahmed

This figure shows the co-authorship network connecting the top 25 collaborators of Esraa A. Ahmed. A scholar is included among the top collaborators of Esraa A. Ahmed based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Esraa A. Ahmed. Esraa A. Ahmed is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ahmed, Esraa A., et al.. (2025). Nebivolol rescued the liver and kidney from the coadministration of rivaroxaban and cisplatin by targeting inflammation, oxidative stress, and apoptosis in rats. International Immunopharmacology. 153. 114486–114486. 2 indexed citations
3.
Ahmed, Esraa A., et al.. (2023). Natural angiotensin converting enzyme inhibitors: A safeguard against hypertension, respiratory distress syndrome, and chronic kidney diseases. Phytotherapy Research. 37(12). 5464–5472. 11 indexed citations
4.
Hetta, ‏Helal F., Yasmin N. Ramadan, Alhanouf I. Al-Harbi, et al.. (2023). Nanotechnology as a Promising Approach to Combat Multidrug Resistant Bacteria: A Comprehensive Review and Future Perspectives. Biomedicines. 11(2). 413–413. 180 indexed citations breakdown →
5.
Ahmed, Esraa A., et al.. (2021). Ameliorative effect of L‐carnitine on chronic lead‐induced reproductive toxicity in male rats. Veterinary Medicine and Science. 7(4). 1426–1435. 26 indexed citations
6.
Ahmed, Esraa A., et al.. (2021). Can granulocyte colony stimulating factor (G-CSF) ameliorate acetaminophen-induced hepatotoxicity?. Human & Experimental Toxicology. 40(10). 1755–1766. 1 indexed citations
7.
Hetta, ‏Helal F., Israa M.S. Al-Kadmy, Ahmed Suhail, et al.. (2021). Antibiofilm and antivirulence potential of silver nanoparticles against multidrug-resistant Acinetobacter baumannii. Scientific Reports. 11(1). 10751–10751. 116 indexed citations
8.
Ahmed, Esraa A., et al.. (2021). Frequency and Impact of DHODH, ABCG2 and CYP2C19 SNPs on the Therapeutic Efficacy, Tolerability and Toxicity of Leflunomide. Pharmacogenomics. 22(18). 1201–1209. 2 indexed citations
9.
Ahmed, Esraa A., et al.. (2020). Anxiolytic activity of methanolic extract of Erythrina variegata Linn. leaves in Wistar rats. 6(1). 108–114. 1 indexed citations
10.
Hetta, ‏Helal F., et al.. (2020). Modulation of Rifampicin-Induced Hepatotoxicity Using Poly(Lactic-Co-Glycolic Acid) Nanoparticles: A Study on Rat and Cell Culture Models. Nanomedicine. 15(14). 1375–1390. 17 indexed citations
11.
Batiha, Gaber El‐Saber, et al.. (2020). <p>Cytotoxic Chemotherapy as an Alternative for Systemic Treatment of Advanced Hepatocellular Carcinoma in Developing Countries</p>. Cancer Management and Research. Volume 12. 12239–12248. 5 indexed citations
12.
Gomaa, Adel A., et al.. (2020). Evaluation of the neuroprotective effect of donepezil in type 2 diabetic rats. Fundamental and Clinical Pharmacology. 35(1). 97–112. 19 indexed citations
13.
Ahmed, Esraa A., et al.. (2019). The protective role of l-carnitine against 1st- and 2nd-generation antihistamine-induced liver injury in mice. Comparative Clinical Pathology. 29(1). 213–221. 5 indexed citations
14.
Ragab, Sameh M., et al.. (2019). Uranium exposure increases spermatocytes metaphase apoptosis in rats: inhibitory effect of thymoquinone and N-acetylcysteine. General Physiology and Biophysics. 38(2). 145–155. 6 indexed citations
15.
Ahmed, Marwa A., et al.. (2019). Alleviation of Simvastatin-Induced Myopathy in Rats by the Standardized Extract of Ginkgo Biloba (EGb761): Insights into the Mechanisms of Action. Cells Tissues Organs. 208(3-4). 158–176. 6 indexed citations
16.
Ellah, Noura H. Abd, et al.. (2019). <p>Metoclopramide nanoparticles modulate immune response in a diabetic rat model: association with regulatory T cells and proinflammatory cytokines</p>. International Journal of Nanomedicine. Volume 14. 2383–2395. 22 indexed citations
17.
Ahmed, Esraa A., et al.. (2019). The possible protective effects of vitamin D and L-carnitine against used atorvastatin-induced myopathy and hepatotoxicity. Comparative Clinical Pathology. 28(6). 1751–1759. 5 indexed citations
18.
Hetta, ‏Helal F., Esraa A. Ahmed, Rasha B. Abd-ellatief, et al.. (2018). Visfatin Serum Levels in Obese Type 2 Diabetic Patients: Relation to Proinflammatory Cytokines and Insulin Resistance.. PubMed. 25(2). 141–151. 21 indexed citations
20.
Gomaa, Adel A., et al.. (2006). The immunopotentiator effects of nefopam. International Immunopharmacology. 7(2). 266–271. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026